Normobaric Hyperoxia Slows Blood-Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia

Stroke

Volumn 46, Issue 5, 2015, Pages 1344-1351

  Liu, Ke Jian ^a,c,d   Liang, Jia ^a,b   Qi, Zhifeng ^a   Liu, Wenlan ^c   Wang, Peng ^b   Shi, Wenjuan ^a   Dong, Wen ^a   Ji, Xunming ^a   Luo, Yumin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

blood brain barrier; ischemia; matrix metalloproteinase 9; tissue type plasminogen activator

Indexed keywords

CLUADIN 5; GELATIN; GELATINASE B; HEMOGLOBIN; OCCLUDIN; OXYGEN; TIGHT JUNCTION PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE SEVERITY; EXTRAVASATION; HEMOGLOBIN BLOOD LEVEL; HYPEROXIA; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; OXYGEN TENSION; PATHOGENESIS; PRIORITY JOURNAL; RAT; REPERFUSION; TREATMENT OUTCOME; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; COMPLICATION; DRUG EFFECTS; FIBRINOLYTIC THERAPY; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; OXYGEN THERAPY; PATHOLOGY; PROCEDURES; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT; TIME TO TREATMENT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MATRIX METALLOPROTEINASE 9; OXYGEN INHALATION THERAPY; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84937243341     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.008599     Document Type: Article

References (32)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
2. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.
3. Alberts MJ. tPA in acute ischemic stroke: United States experience and issues for the future. Neurology. 1998;51(3 suppl 3):S53-S55.
4. Jin X, Liu J, Yang Y, Liu KJ, Yang Y, Liu W. Spatiotemporal evolution of blood brain barrier damage and tissue infarction within the first 3h after ischemia onset. Neurobiol Dis. 2012;48:309-316. doi: 10.1016/j. nbd.2012.07.007.
5. Henninger N, Sicard KM, Fisher M. Spectacular shrinking deficit: insights from multimodal magnetic resonance imaging after embolic middle cerebral artery occlusion in Sprague-Dawley rats. J Cereb Blood Flow Metab. 2007;27:1756-1763. doi: 10.1038/sj.jcbfm.9600477.
6. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35(11 suppl 1):2726-2730. doi: 10.1161/01.STR.0000143219.16695.a.f.
7. Poli S, Veltkamp R. Oxygen therapy in acute ischemic stroke-experimental efficacy and molecular mechanisms. Curr Mol Med. 2009;9:227-241.
8. Henninger N, Fisher M. Normobaric hyperoxia-a promising approach to expand the time window for acute stroke treatment. Cerebrovasc Dis. 2006;21:134-136. doi: 10.1159/000090446.
9. Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2007;27:1632-1642. doi: 10.1038/sj.jcbfm.9600463.
10. Liu S, Shi H, Liu W, Furuichi T, Timmins GS, Liu KJ. Interstitial pO2 in ischemic penumbra and core are differentially affected following transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2004;24:343-349. doi: 10.1097/01.WCB.0000110047.43905.01.
11. Singhal AB. A review of oxygen therapy in ischemic stroke. Neurol Res. 2007;29:173-183. doi: 10.1179/016164107X181815.
12. Wu O, Lu J, Mandeville JB, Murata Y, Egi Y, Dai G, et al. Dynamic functional cerebral blood volume responses to normobaric hyperoxia in acute ischemic stroke. J Cereb Blood Flow Metab. 2012;32:1800-1809. doi: 10.1038/jcbfm.2012.87.
13. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, et al. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005;36:797-802. doi: 10.1161/01. STR.0000158914.66827.2e.
14. Liu W, Sood R, Chen Q, Sakoglu U, Hendren J, Cetin O, et al. Normobaric hyperoxia inhibits NADPH oxidase-mediated matrix metalloproteinase-9 induction in cerebral microvessels in experimental stroke. J Neurochem. 2008;107:1196-1205. doi: 10.1111/j.1471-4159.2008.05664.x.
15. Liu W, Chen Q, Liu J, Liu KJ. Normobaric hyperoxia protects the blood brain barrier through inhibiting Nox2 containing NADPH oxidase in ischemic stroke. Med Gas Res. 2011;1:22. doi: 10.1186/2045-9912-1-22.
16. Liu W, Hendren J, Qin XJ, Shen J, Liu KJ. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem. 2009;108:811-820. doi: 10.1111/j.1471-4159.2008.05821.x.
17. Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012;32:3044-3057. doi: 10.1523/JNEUROSCI.6409-11.2012.
18. Liu W, Hendren J, Qin XJ, Liu KJ. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke. 2009;40:2526-2531. doi: 10.1161/STROKEAHA.108.545483.
19. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003;34:2025-2030. doi: 10.1161/01.STR.0000083051.93319.28.
20. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372-3377. doi: 10.1161/STROKEAHA.108.514026.
21. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
22. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 1996;27:1616-1622, discussion 1623.
23. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10:290-293. doi: 10.1038/jcbfm.1990.47.
24. Qin Z, Karabiyikoglu M, Hua Y, Silbergleit R, He Y, Keep RF, et al. Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia. Stroke. 2007;38:1362-1367. doi: 10.1161/01.STR.0000259660.62865.e.b.
25. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27:697-709. doi: 10.1038/sj.jcbfm.9600375.
26. Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ. Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2006;26:1274-1284. doi: 10.1038/sj.jcbfm.9600277.
27. Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005;57:571-575. doi: 10.1002/ana.20430.
28. Singhal AB, Wang X, Sumii T, Mori T, Lo EH. Effects of normobaric hyperoxia in a rat model of focal cerebral ischemiareperfusion. J Cereb Blood Flow Metab. 2002;22:861-868. doi: 10.1097/00004647-200207000-00011.
29. Qi Z, Liu W, Luo Y, Ji X, Liu KJ. Normobaric hyperoxia-based neuroprotective therapies in ischemic stroke. Med Gas Res. 2013;3:2. doi: 10.1186/2045-9912-3-2.
30. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007;22:E4.
31. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258-268. doi: 10.1016/S1474-4422(07)70055-8.
32. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.